




JPW

| | | | |
|---|----------------------|------------------------|---------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | Application Number | 10/551,004 | |
| | Filing Date | September 26, 2005 | |
| | First Named Inventor | Henning Walczak | |
| | Group Art Unit | 1644 | |
| | Examiner Name | Unassigned | |
| Total Number of Pages in This Submission | 4 + Refs. | Attorney Docket Number | 045278-002000 |

| ENCLOSURES (check all that apply) | | |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement with PTO-1449 <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input type="checkbox"/> Request for Corrected Filing Receipt with Enclosures <input checked="" type="checkbox"/> A self-addressed prepaid postcard for acknowledging receipt <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): References (16) |
| Remarks | | <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any fees required or credit any overpayments to Deposit Account No. 19-2380 for the above identified docket number. |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | |
|--|--|
| Firm or Individual name | Birgit Millauer – Reg. No. 43,341 Nixon Peabody LLP 401 9 th Street, N.W. Suite 900 Washington, D.C. 20004-2128 |
| Signature | |
| Date | August 10, 2007 |

| CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)] | |
|---|-----------------------------------|
| I hereby certify that this correspondence is being: | |
| <input checked="" type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 | |
| <input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (571) 273-8300 | |
| August 10, 2007 Date | Signature Helen A. Jackson |



Application No. 10/551,004
Attorney Docket No. : 045278-002000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|----------------------------------|--------------------------|
| In re Patent Application of: |) Confirmation No.: 1454 |
| Henning Walczak |) Examiner: Unassigned |
| Application No.: 10/551,004 |) Group Art Unit: 1644 |
| Filed: September 26, 2005 |) Customer No.: 22204 |
| For: IMPROVED FC FUSION PROTEINS |) |

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being transmitted to the United States Patent and Trademark Office via first class mail on 8-10-07.

Signature: Helen A. Jackson

NIXON PEABODY LLP

Name: Helen A. Jackson

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initial a copy of this form and return it to the undersigned

The Commissioner is hereby authorized to charge any fees connected with this Information Disclosure Statement which may be required now, or credit any overpayment, to Deposit Account No. 50-3557.

Respectfully submitted,



Birgit Millauer
Registration No. 43,341

NIXON PEABODY LLP
Suite 900
401 9th Street, N.W.
Washington, DC 20004-2128
Telephone: (202) 585-8000



| | | | | | |
|--|---|----|----|--------------------------|------------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | |
| | | | | Filing Date | |
| | | | | First Named Inventor | |
| | | | | Art Unit | |
| | | | | Examiner Name | |
| Sheet | 1 | of | B1 | 1 | Attorney Docket Number |

| U.S. PATENT DOCUMENTS | | | | | |
|--------------------------------|-----------------------|--|--------------------------------|--|--|
| Examiner Initials ¹ | Cite No. ¹ | U.S. Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | A1 | US-6,015,559 | 01/18/2000 | Lynch, et al. | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------------|-----------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | B1 | WO 02/090553 | 11/14/2002 | Erfinder, et al. | | |
| | B2 | WO 02/079415 | 10/10/2002 | Gillies | | |
| | B3 | WO 02/066514 | 08/29/2002 | Gillies, et al. | | |
| | B4 | WO 01/49866 | 07/12/2001 | Erfinder, et al. | | |
| | B5 | WO 01/41803 A1 | 06/14/2001 | Erfinder, et al. | | |
| | B6 | EP 0 992 243 | 04/12/2000 | Nagata, et al. | | |
| | B7 | WO 00/18932 | 04/06/2000 | Stahl, et al. | | |
| | B8 | EP 0 965 637 | 12/22/1999 | Nakamura, et al. | | |
| | B9 | WO 99/50413 | 10/07/1999 | Bumol, et al. | | |
| | B10 | WO 98/36768 | 08/27/1998 | Grooten, et al. | | |
| | B11 | WO 95/27735 | 10/19/1995 | Krammer, et al. | | |
| | B12 | EP 0 526 452 | 02/10/1993 | Capon, et al. | | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C1 | DEMJEN, D <i>et al.</i> , "Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury", <i>Nat. Med</i> 10(4):389-395, 2004. | |
| | C2 | KIM, Yon Su <i>et al.</i> , "Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fc 2a Protein Blocks Delayed-Type Hypersensitivity", <i>J. Immunol</i> 160:5742-5748, 1998. | |
| | C3 | MARTIN-VILLALBA, A. <i>et al.</i> , "Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke", <i>Cell Death Differ.</i> 8(7):679-686, 2001. | |
| | C4 | SMITH, CA <i>et al.</i> , "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family cytokines with homology to TNF", <i>Cell</i> 73(7):1349-1360, 1993 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.